CPIX

+ Watchlist + Portfolio

Cumberland Pharmaceuticals Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.65
52-Week Range: $1.85 – $8.45
Market Cap: $112.37M
P/E (TTM): —
EPS (TTM): -0.22
Dividend Yield: —

Advanced Metrics

Price/Book: 6.44
PEG Ratio: 1.67
Return on Equity: -14.39%
Return on Assets: -2.91%
Gross Margin: 84.95%
Operating Margin: -1898.65%
Profit Margin: -24.64%
Current Ratio: 0.96
Debt/Equity: 0.28
Total Debt: $4.71M
Free Cash Flow: $-191.17K
Revenue Growth: -56.30%
Earnings Growth: —
Enterprise Value: $115.14M

CPIX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$42.01M	$39.55M	$37.87M	$44.52M
Cost of Revenue	$9.12M	$6.07M	$6.59M	$6.67M
Gross Profit	$32.89M	$33.49M	$31.28M	$37.85M
Research & Development	$6.69M	$5.83M	$4.82M	$5.57M
Selling, General & Admin	$26.84M	$29.10M	$28.15M	$31.05M
Operating Expenses	$38.60M	$43.04M	$37.71M	$40.65M
Operating Income	-$5.70M	-$9.55M	-$6.43M	-$2.79M
EBITDA	$332.92K	$2.49M	$182.42K	$2.97M
Pretax Income	-$5.58M	-$6.28M	-$6.47M	-$2.81M
Income Tax	$68.85K	$45.77K	-$22.67K	$40.26K
Net Income	-$5.57M	-$6.28M	-$6.48M	-$2.84M
Diluted EPS	-0.38	-0.44	-0.46	-0.19
Diluted Shares	14.56M	14.30M	14.06M	14.85M

CPIX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.76M	$18.32M	$17.96M	$11.44M
Receivables	$13.16M	$9.76M	$11.70M	$16.94M
Inventory	$9.86M	$4.61M	$4.00M	$6.23M
Current Assets	$45.87M	$35.71M	$36.45M	$37.06M
Total Assets	$92.93M	$81.78M	$75.58M	$76.82M
Current Liabilities	$28.58M	$27.98M	$31.62M	$36.74M
Long-Term Debt	$16.20M	$12.78M	$10.18M	$5.24M
Total Debt	$20.96M	$18.43M	$20.57M	$10.18M
Total Liabilities	$56.95M	$52.52M	$53.04M	$52.28M
Retained Earnings	-$11.21M	-$17.49M	-$23.97M	-$26.80M
Shareholders' Equity	$36.27M	$29.60M	$22.85M	$24.88M
Working Capital	$17.29M	$7.73M	$4.83M	$315.35K

CPIX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$8.45M	$6.09M	-$612.19K	$4.93M
Capital Expenditure	-$2.07M	-$453.05K	-$179.71K	-$182.31K
Free Cash Flow	$6.38M	$5.64M	-$791.90K	$4.75M
Depreciation & Amortisation	$5.33M	$5.77M	$6.04M	$5.29M
Stock-Based Compensation	$447.50K	$365.04K	$301.89K	$408.32K
Investing Cash Flow	-$13.67M	-$105.69K	$57.84K	-$4.71M
Financing Cash Flow	-$2.06M	-$7.42M	$196.90K	-$6.75M
Share Repurchases	-$1.05M	-$740.53K	-$579.05K	-$263.48K
Net Change in Cash	-$7.28M	-$1.44M	-$357.44K	-$6.52M

CPIX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$11.71M	$10.84M	$8.29M	$13.68M	$9.13M
Cost of Revenue	$1.43M	$2.01M	$988.76K	$2.24M	$1.93M
Gross Profit	$10.29M	$8.83M	$7.30M	$11.44M	$7.20M
Research & Development	$1.30M	$1.47M	$1.25M	$1.55M	$1.46M
Selling, General & Admin	$6.69M	$7.10M	$7.01M	$10.25M	$7.62M
Operating Expenses	$9.00M	$9.57M	$9.27M	$12.81M	$10.33M
Operating Income	$1.29M	-$747.48K	-$1.97M	-$1.37M	-$3.13M
EBITDA	$2.73M	$699.11K	-$510.69K	$47.84K	-$1.49M
Pretax Income	$1.25M	-$729.54K	-$1.94M	-$1.39M	-$3.14M
Income Tax	$5.67K	$5.67K	$5.67K	$23.25K	$3.87K
Net Income	$1.26M	-$740.74K	-$1.94M	-$1.41M	-$3.29M
Diluted EPS	0.08	-0.05	-0.13	-0.09	-0.22
Diluted Shares	15.26M	14.96M	14.96M	14.96M	14.96M

CPIX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$15.11M	$16.09M	$15.20M	$11.44M	$11.01M
Receivables	$10.49M	$10.32M	$10.43M	$16.94M	$14.26M
Inventory	$4.10M	$3.22M	$2.93M	$6.23M	$5.45M
Current Assets	$31.88M	$31.21M	$29.94M	$37.06M	$32.79M
Total Assets	$69.94M	$67.91M	$65.90M	$76.82M	$71.00M
Current Liabilities	$25.52M	$23.97M	$24.31M	$36.74M	$34.49M
Long-Term Debt	$5.24M	$5.24M	$5.24M	$5.24M	$5.24M
Total Debt	$10.44M	$10.34M	$10.24M	$10.18M	$10.07M
Total Liabilities	$41.60M	$40.23M	$40.10M	$52.28M	$49.69M
Retained Earnings	-$22.71M	-$23.45M	-$25.39M	-$26.80M	-$30.09M
Shareholders' Equity	$28.66M	$27.99M	$26.12M	$24.88M	$21.64M
Working Capital	$6.36M	$7.23M	$5.63M	$315.35K	-$1.70M

CPIX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$3.90M	$843.80K	$187.18K	$3.02K	$387.02K
Capital Expenditure	-$1.23M	—	-$32.24K	-$43.84K	-$19.16K
Free Cash Flow	$2.67M	$1.97M	$154.94K	-$40.82K	$367.87K
Depreciation & Amortisation	$1.32M	$1.32M	$1.32M	$1.33M	$1.56M
Stock-Based Compensation	$74.21K	$80.69K	$81.26K	$172.16K	$106.84K
Investing Cash Flow	-$1.23M	$285.86K	-$690.84K	-$3.07M	-$61.17K
Financing Cash Flow	-$5.53M	-$150.80K	-$386.88K	-$681.74K	-$763.30K
Share Repurchases	-$245.87K	-$7.17K	-$10.44K	$0.00	-$61.00K
Net Change in Cash	-$2.86M	$978.87K	-$890.54K	-$3.75M	-$437.45K

Market Snapshot

About

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for acute care and gastroenterology. Headquartered in Nashville, Tennessee, the company markets products including Caldolor (ibuprofen injection) for pain and fever, Vibativ (telavancin) for serious bacterial infections, and Kristalose (lactulose) for chronic constipation. Cumberland targets hospital acute care settings and the gastroenterology market with products addressing conditions that often lack effective treatments. The company employs a focused commercial strategy with specialized sales teams serving healthcare providers.